5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment

By Ekta Bagri | July 02, 2025, 9:28 AM

Immunocore Holdings plc ADR

Kiniksa Pharmaceuticals International Plc

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Exelixis, Inc. (EXEL): Free Stock Analysis Report

Alkermes plc (ALKS): Free Stock Analysis Report

Verona Pharma PLC American Depositary Share (VRNA): Free Stock Analysis Report

Kiniksa Pharmaceuticals International, plc (KNSA): Free Stock Analysis Report

Immunocore Holdings PLC Sponsored ADR (IMCR): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Mentioned In This Article

Immunocore Holdings plc ADR

Kiniksa Pharmaceuticals International Plc

Latest News

7 hours	Exelixis Hits High on Growing Sales, Institutional Inflows EXEL FX Empire
Jun-04	Alkermes to Present New Data on Alixorexton and LUMRYZ (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research ALKS Business Wire
Jun-03	Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference ALKS Business Wire
May-31	Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma IMCR GlobeNewswire
May-30	Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026 EXEL Business Wire
May-29	Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences KNSA GlobeNewswire
May-27	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June EXEL Business Wire
May-26	Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting ALKS Business Wire
May-21	Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types EXEL Business Wire
May-21	Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences ALKS Business Wire
May-19	Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer EXEL Business Wire
May-12	Alkermes Announces Positive Topline Results From REVITALYZ Phase 3 Study Evaluating LUMRYZ (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia ALKS +7.95% Business Wire
May-07	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May EXEL -5.11% Business Wire
May-06	Immunocore reports first quarter financial results and provides a business update IMCR +6.55% GlobeNewswire
May-05	Exelixis, Inc. Q1 2026 Earnings Call Summary EXEL Moby

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)